What are the benefits of BPC-157?

Marketing claims include injury healing and gut repair. Review literature states efficacy has not been confirmed in humans and that approval is lacking due to insufficient clinical studies. Most positive data are preclinical.

Does BPC-157 heal tendons?

There is substantial rodent and mechanistic interest in tissue repair. That is not the same as proven human tendon therapy. Treat human benefit claims as unproven until high-quality trials exist.

Is BPC-157 worth taking?

This site does not recommend research chemicals. Legal status, purity, and thin human evidence are material. Discuss health decisions with a clinician.

Research peptidesbpc-157 benefits

BPC-157 Benefits: What the Research Has Found

BPC-157 has one of the largest healing literatures in animal research. What those studies found, how small the human record is, and how to read the gap.

Written bySebastian Hunter, Founder and Editor

Published July 16, 2026Updated August 22, 2026

Start here

Plain English

BPC-157 has an unusually large animal literature on tissue healing, across tendon, gut and muscle models, which is why interest in it runs so high. The human record is far smaller, and reviews state that efficacy in people is not yet confirmed. It is not approved for human use, and legality and purity matter as much as the biology.

The animal literature is genuinely large. The human literature is not.
Reviews state that efficacy in humans is not yet confirmed, and approval is lacking.
It is not an approved medicine or supplement, and vendor purity varies.

BPC-157 benefits are described online with more confidence than the research supports, and with less curiosity than the research deserves. Both of those are true at once, so this page separates them.

Start with what exists, because it is substantial. A review of the musculoskeletal literature describes BPC-157 accelerating soft-tissue healing across the published models. Gwyer 2019 - Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159. (opens PubMed in a new tab) Separate work reports a proposed angiogenic mechanism through VEGFR2 signalling. Hsieh 2017 - Hsieh MJ, Liu HT, Wang CN et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. (opens PubMed in a new tab) That is a real body of preclinical research, and it is why the compound gets the attention it does.

Then the part the product pages skip. BPC stands for body protection compound, which is the name researchers gave it rather than a benefit demonstrated in anyone. Those models are overwhelmingly small rodents, and the reviews are explicit about what that leaves unsettled.

What the reviews say

The same 2019 review notes that most work is in small rodent models and that efficacy is yet to be confirmed in humans. Gwyer 2019 - Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159. (opens PubMed in a new tab)

A 2025 review states BPC-157 has not been approved by the FDA and other authorities due to the absence of sufficient and comprehensive clinical studies confirming health benefits in humans. Józwiak 2025 - Józwiak M, Bauer M, Kamysz W et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals (Basel). 2025;18(2). (opens PubMed in a new tab)

Mechanistic and animal work continues, including the angiogenesis-related pathways above. Hsieh 2017 - Hsieh MJ, Liu HT, Wang CN et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. (opens PubMed in a new tab) That is an active research programme, and it is the reason to watch this compound rather than a reason to treat the question as settled.

Full evidence page: BPC-157

Claimed benefits vs evidence class

Marketed benefit	Evidence class we can defend
Soft-tissue healing	Mostly preclinical
Gut repair	Historical clinical interest; not a finished modern package
”No side effects”	Absence of reports ≠ proven long-term human safety
Sports recovery	WADA banned (S0) - not a wellness green light

Limited human data

Small or uncontrolled human studies. Too little to settle the question either way. Large preclinical literature; human efficacy not confirmed per review authors; not approved as a medicine.

Legal reality (US)

Not FDA-approved for any indication. Sold as research chemical / RUO. Banned in sport under WADA S0.

See research peptides and the law · BPC vs TB-500

References

Bibliographic detail is fetched from PubMed, not written by us - so a citation here cannot drift from the paper it names. Study design comes from PubMed's own tags rather than our judgement.

1.Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159.ReviewPMID 30915550
2.Józwiak M, Bauer M, Kamysz W et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals (Basel). 2025;18(2).ReviewPMID 40005999full text
3.Hsieh MJ, Liu HT, Wang CN et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333.StudyPMID 27847966
4.WADA 2026 Prohibited List - BPC-157 under S0 Non-Approved Substances (national anti-doping agency mirror, PDF).- World Anti-Doping Agency (mirrored by the Jamaica Anti-Doping Commission)regulatory